Chibroxin

(Norfloxacin)

ApprovedSmall molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Chibroxin is one of 43 small molecule programs targeting Urinary Tract Infection. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Urinary Tract InfectionActive, not recruiting

PeritonitisCompleted

Urinary Tract InfectionApproved

Active, not recruiting

PeritonitisApproved

Completed

Competition

Competitive Landscape

39 competitors in Urinary Tract Infection

#DrugCompanyPhaseTrials

Doribax

Shionogi

Approved

6 2

Cipro

Bayer

Approved

6 3

Levaquin

WWim Janssens

Approved

14 4

Ivadantin

PProcter and Gamble

Approved

12 5

Estrace

Novo Nordisk

Approved

2 6

Vesicare

Astellas

Approved

1 7

Voltaren

Novartis

Approved

1 8

Acanya

Pfizer

Approved

1 9

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

6 10

Flomax

Sanofi

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Peritonitis

NCT04161768

Clinical

Trials by Indication[1]

Peritonitis7 trials

Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis

Completed·HHospital Clinic of Barcelona·Phase 4·NCT00359853·70 enrolled

Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Recruiting·TTanta University·Phase 3·NCT04161768·80 enrolled

Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis

Unknown status·OOspedali Riuniti di Foggia·Phase 3·NCT04159870·322 enrolled

Show 4 more trials

Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention

Completed·KKorea University·Phase 4·NCT01542801·124 enrolled

Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis

Unknown status·TTanta University·Phase 3·NCT04746937·60 enrolled

Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Unknown status·SSherief Abd-Elsalam·Phase 3·NCT02120196·100 enrolled

Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03702426·120 enrolled

Prophylaxis2 trials

Comparative Study of Secondary Prophylaxis for SBP

Completed·TTanta University·Phase 4·NCT06827756·90 enrolled

Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06199843·280 enrolled

Efficacy and Safety1 trial

Noroxin Efficacy and Safety Trial

Unknown status·OOBS Pakistan·Phase 4·NCT03506256·1,000 enrolled

Liver Failure1 trial

Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT01037959·291 enrolled

Urinary Tract Infection1 trial

Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.

Terminated·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT01039545·253 enrolled

3 more indications

Cystitis1 trial

Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)

Withdrawn·EEurofarma Laboratorios S.A.·Phase 3·NCT01527019

Peptides1 trial

Vasoactive Peptides in Portal Pressure

Unknown status·BBayside Health·N/A·NCT00163982

Hepatopulmonary Syndrome1 trial

A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome

Completed·UUnity Health Toronto·Phase 2·NCT00362752·9 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 31, 1986

NOROXIN

NDA NDA019384

Jun 17, 1991

CHIBROXIN

NDA NDA019757

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Norfloxacin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Norfloxacin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Norfloxacin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019757). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Chibroxin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Peritonitis7 trials

Prophylaxis2 trials

Efficacy and Safety1 trial

Liver Failure1 trial

Urinary Tract Infection1 trial

Cystitis1 trial

Peptides1 trial

Hepatopulmonary Syndrome1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News